Korean J Physiol Pharmacol.  2018 Jan;22(1):63-70. 10.4196/kjpp.2018.22.1.63.

Cilostazol attenuates kainic acid-induced hippocampal cell death

Affiliations
  • 1Department of Neurosurgery, Institute of Health Sciences, Gyeongsang National University Changwon Hospital, Changwon 51472, Korea.
  • 2Department of Anatomy and Convergence Medical Science, Institute of Health Sciences, Gyeongsang National University College of Medicine, Jinju 52727, Korea. anaroh@gnu.ac.kr
  • 3Department of Neurosurgery, Institute of Health Sciences, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju 52727, Korea. gnuhpis@gnu.ac.kr

Abstract

Cilostazol is a selective inhibitor of type 3 phosphodiesterase (PDE3) and has been widely used as an antiplatelet agent. Cilostazol mediates this activity through effects on the cyclic adenosine monophosphate (cAMP) signaling cascade. Recently, it has attracted attention as a neuroprotective agent. However, little is known about cilostazol's effect on excitotoxicity induced neuronal cell death. Therefore, this study evaluated the neuroprotective effect of cilostazol treatment against hippocampal neuronal damage in a mouse model of kainic acid (KA)-induced neuronal loss. Cilostazol pretreatment reduced KA-induced seizure scores and hippocampal neuron death. In addition, cilostazol pretreatment increased cAMP response element-binding protein (CREB) phosphorylation and decreased neuroinflammation. These observations suggest that cilostazol may have beneficial therapeutic effects on seizure activity and other neurological diseases associated with excitotoxicity.

Keyword

Cilostazol; Hippocampus; Kainic acid; Neuroinflammation; Neuronal death

MeSH Terms

Adenosine Monophosphate
Animals
Cell Death*
Cyclic AMP Response Element-Binding Protein
Hippocampus
Kainic Acid
Mice
Neurons
Neuroprotective Agents
Phosphorylation
Seizures
Therapeutic Uses
Adenosine Monophosphate
Cyclic AMP Response Element-Binding Protein
Kainic Acid
Neuroprotective Agents
Therapeutic Uses

Figure

  • Fig. 1 Effect of cilostazol pretreatment on seizure activity and hippocampal cell death in KA-treated mice.(A) Behavioral seizure scores over time were monitored for 2 h after KA treatment. Data are presented as the mean±SEM. *p<0.05 versus CTL. (B) Representative microphotographs of Cresyl violet and TUNEL staining. Cresyl violet staining shows specific neuronal loss in the CA3 region of KA-treated mice. The areas in black squares in left panels were magnified on the central panels. TUNEL-positive cells indicate neuronal cell death in KA-treated hippocampus. Scale bar=100 µm.

  • Fig. 2 Effect of cilostazol pretreatment on phosphorylated CREB expression in KA-treated hippocampus.Western blots of hippocampal pCREB and CREB. The mean densitometry values were obtained from three separate experiments (n=6 mice per group). Data are presented as the mean±SEM. *p<0.05 vs. CTL.

  • Fig. 3 Effect of cilostazol pretreatment on LCN2 and GFAP expression in KA-treated hippocampus.Western blots and protein quantification of hippocampal LCN2 (A) and GFAP (B). The mean densitometry values were obtained from three separate experiments (n=6 mice per group). Data are presented as the mean±SEM. *p<0.05 vs. CTL. †p<0.05 vs. KA. (C) Representative images of triple-immunofluorescence staining for LCN2 (red), GFAP (purple), and Iba1 (green) in the CA3 region of hippocampus of CTL, KA, KA+Cilo, and Cilo mice. Scale bar=50 µm. (D) Representative images of LCN2 (red), GFAP (purple), and Iba1 (green)-positive cells in the CA3 region of hippocampus of KA-treated mice. Scale bar=10 µm.

  • Fig. 4 Effect of cilostazol pretreatment on COX-2 and TGF-β1 expression in KA-treated hippocampus.Western blots and protein quantification of hippocampal COX-2 (A) and TGF-β1 (B). The mean values were obtained from three separate experiments (n=6 mice per group). Data are presented as the mean±SEM. *p<0.05 vs. CTL. †p<0.05 vs. KA.


Reference

1. Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung. 1985; 35:1144–1149. PMID: 4074426.
2. Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwiec F. Cilostazol as a unique antithrombotic agent. Curr Pharm Des. 2003; 9:2289–2302. PMID: 14529391.
Article
3. Miyamoto N, Tanaka R, Shimura H, Watanabe T, Mori H, Onodera M, Mochizuki H, Hattori N, Urabe T. Phosphodiesterase III inhibition promotes differentiation and survival of oligodendrocyte progenitors and enhances regeneration of ischemic white matter lesions in the adult mammalian brain. J Cereb Blood Flow Metab. 2010; 30:299–310. PMID: 19826432.
Article
4. Lee JH, Park SY, Shin YW, Hong KW, Kim CD, Sung SM, Kim KY, Lee WS. Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion. Brain Res. 2006; 1082:182–191. PMID: 16516167.
Article
5. Qi DS, Tao JH, Zhang LQ, Li M, Wang M, Qu R, Zhang SC, Liu P, Liu F, Miu JC, Ma JY, Mei XY, Zhang F. Neuroprotection of Cilostazol against ischemia/reperfusion-induced cognitive deficits through inhibiting JNK3/caspase-3 by enhancing Akt1. Brain Res. 2016; 1653:67–74. PMID: 27769787.
Article
6. Nadler JV, Perry BW, Cotman CW. Intraventricular kainic acid preferentially destroys hippocampal pyramidal cells. Nature. 1978; 271:676–677. PMID: 625338.
Article
7. Rizzi M, Perego C, Aliprandi M, Richichi C, Ravizza T, Colella D, Velískŏvá J, Moshe SL, De Simoni MG, Vezzani A. Glia activation and cytokine increase in rat hippocampus by kainic acid-induced status epilepticus during postnatal development. Neurobiol Dis. 2003; 14:494–503. PMID: 14678765.
Article
8. Kim H, Lee JY, Park KJ, Kim WH, Roh GS. A mitochondrial division inhibitor, Mdivi-1, inhibits mitochondrial fragmentation and attenuates kainic acid-induced hippocampal cell death. BMC Neurosci. 2016; 17:33. PMID: 27287829.
Article
9. Shin HJ, Lee JY, Son E, Lee DH, Kim HJ, Kang SS, Cho GJ, Choi WS, Roh GS. Curcumin attenuates the kainic acid-induced hippocampal cell death in the mice. Neurosci Lett. 2007; 416:49–54. PMID: 17300872.
Article
10. Chia WJ, Dawe GS, Ong WY. Expression and localization of the iron-siderophore binding protein lipocalin 2 in the normal rat brain and after kainate-induced excitotoxicity. Neurochem Int. 2011; 59:591–599. PMID: 21683107.
Article
11. Lull ME, Block ML. Microglial activation and chronic neurodegeneration. Neurotherapeutics. 2010; 7:354–365. PMID: 20880500.
Article
12. Lee S, Park JY, Lee WH, Kim H, Park HC, Mori K, Suk K. Lipocalin-2 is an autocrine mediator of reactive astrocytosis. J Neurosci. 2009; 29:234–249. PMID: 19129400.
Article
13. Borkham-Kamphorst E, Drews F, Weiskirchen R. Induction of lipocalin-2 expression in acute and chronic experimental liver injury moderated by pro-inflammatory cytokines interleukin-1β through nuclear factor-κB activation. Liver Int. 2011; 31:656–665. PMID: 21457438.
Article
14. Yoneyama M, Tanaka M, Hasebe S, Yamaguchi T, Shiba T, Ogita K. Beneficial effect of cilostazol-mediated neuronal repair following trimethyltin-induced neuronal loss in the dentate gyrus. J Neurosci Res. 2015; 93:56–66. PMID: 25139675.
Article
15. Jeong EA, Jeon BT, Shin HJ, Kim N, Lee DH, Kim HJ, Kang SS, Cho GJ, Choi WS, Roh GS. Ketogenic diet-induced peroxisome proliferator-activated receptor-γ activation decreases neuroinflammation in the mouse hippocampus after kainic acid-induced seizures. Exp Neurol. 2011; 232:195–202. PMID: 21939657.
Article
16. Kim YR, Kim HN, Hong KW, Shin HK, Choi BT. Anti-depressant effects of phosphodiesterase 3 inhibitor cilostazol in chronic mild stress-treated mice after ischemic stroke. Psychopharmacology (Berl). 2016; 233:1055–1066. PMID: 26686236.
Article
17. Ben-Ari Y. Limbic seizure and brain damage produced by kainic acid: mechanisms and relevance to human temporal lobe epilepsy. Neuroscience. 1985; 14:375–403. PMID: 2859548.
Article
18. Morgan TE, Nichols NR, Pasinetti GM, Finch CE. TGF-β1 mRNA increases in macrophage/microglial cells of the hippocampus in response to deafferentation and kainic acid-induced neurodegeneration. Exp Neurol. 1993; 120:291–301. PMID: 8491285.
Article
19. Tanaka Y, Tanaka R, Liu M, Hattori N, Urabe T. Cilostazol attenuates ischemic brain injury and enhances neurogenesis in the subventricular zone of adult mice after transient focal cerebral ischemia. Neuroscience. 2010; 171:1367–1376. PMID: 20933581.
Article
20. Liu Y, Shakur Y, Yoshitake M, Kambayashi Ji J. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev. 2001; 19:369–386. PMID: 11830753.
Article
21. Watanabe T, Zhang N, Liu M, Tanaka R, Mizuno Y, Urabe T. Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion. Stroke. 2006; 37:1539–1545. PMID: 16645134.
Article
22. Nakagawa S, Kim JE, Lee R, Malberg JE, Chen J, Steffen C, Zhang YJ, Nestler EJ, Duman RS. Regulation of neurogenesis in adult mouse hippocampus by cAMP and the cAMP response element-binding protein. J Neurosci. 2002; 22:3673–3682. PMID: 11978843.
Article
23. Tanis KQ, Duman RS, Newton SS. CREB binding and activity in brain: regional specificity and induction by electroconvulsive seizure. Biol Psychiatry. 2008; 63:710–720. PMID: 17936724.
Article
24. Moore AN, Waxham MN, Dash PK. Neuronal activity increases the phosphorylation of the transcription factor cAMP response element-binding protein (CREB) in rat hippocampus and cortex. J Biol Chem. 1996; 271:14214–14220. PMID: 8662977.
Article
25. Pardo L, Schlüter A, Valor LM, Barco A, Giralt M, Golbano A, Hidalgo J, Jia P, Zhao Z, Jové M, Portero-Otin M, Ruiz M, Giménez-Llort L, Masgrau R, Pujol A, Galea E. Targeted activation of CREB in reactive astrocytes is neuroprotective in focal acute cortical injury. Glia. 2016; 64:853–874. PMID: 26880229.
Article
26. Watanabe T, Zhang N, Liu M, Tanaka R, Mizuno Y, Urabe T. Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion. Stroke. 2006; 37:1539–1545. PMID: 16645134.
Article
27. Tanaka K, Nogawa S, Ito D, Suzuki S, Dembo T, Kosakai A, Fukuuchi Y. Activated phosphorylation of cyclic AMP response element binding protein is associated with preservation of striatal neurons after focal cerebral ischemia in the rat. Neuroscience. 2000; 100:345–354. PMID: 11008172.
Article
28. Chen Z, Duan RS, Quezada HC, Mix E, Nennesmo I, Adem A, Winblad B, Zhu J. Increased microglial activation and astrogliosis after intranasal administration of kainic acid in C57BL/6 mice. J Neurobiol. 2005; 62:207–218. PMID: 15459893.
Article
29. Stienen MN, Haghikia A, Dambach H, Thone J, Wiemann M, Gold R, Chan A, Dermietzel R, Faustmann PM, Hinkerohe D, Prochnow N. Anti-inflammatory effects of the anticonvulsant drug levetiracetam on electrophysiological properties of astroglia are mediated via TGFβ1 regulation. Br J Pharmacol. 2011; 162:491–507. PMID: 20955362.
Article
30. Laping NJ, Nichols NR, Day JR, Finch CE. Corticosterone differentially regulates the bilateral response of astrocyte mRNAs in the hippocampus to entorhinal cortex lesions in male rats. Brain Res Mol Brain Res. 1991; 10:291–297. PMID: 1717807.
Article
31. Prehn JH, Miller RJ. Opposite effects of TGF-β1 on rapidly- and slowly-triggered excitotoxic injury. Neuropharmacology. 1996; 35:249–256. PMID: 8783198.
Article
32. Wang XS, Ong WY, Connor JR. Increase in ferric and ferrous iron in the rat hippocampus with time after kainate-induced excitotoxic injury. Exp Brain Res. 2002; 143:137–148. PMID: 11880890.
Article
33. Huang E, Ong WY. Distribution of ferritin in the rat hippocampus after kainate-induced neuronal injury. Exp Brain Res. 2005; 161:502–511. PMID: 15747160.
Article
34. Chia WJ, Tan FC, Ong WY, Dawe GS. Expression and localisation of brain-type organic cation transporter (BOCT/24p3R/LCN2R) in the normal rat hippocampus and after kainate-induced excitotoxicity. Neurochem Int. 2015; 87:43–59. PMID: 26004810.
Article
35. Takemiya T, Maehara M, Matsumura K, Yasuda S, Sugiura H, Yamagata K. Prostaglandin E2 produced by late induced COX-2 stimulates hippocampal neuron loss after seizure in the CA3 region. Neurosci Res. 2006; 56:103–110. PMID: 16837093.
Article
Full Text Links
  • KJPP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr